135 related articles for article (PubMed ID: 12097539)
1. Clinical practice. Long-term care after hematopoietic-cell transplantation in adults.
Antin JH
N Engl J Med; 2002 Jul; 347(1):36-42. PubMed ID: 12097539
[No Abstract] [Full Text] [Related]
2. Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease.
Davies JK; Taussig DC; Oakervee H; Davies AJ; Agrawal SG; Gribben JG; Lister TA; Cavenagh JD
J Clin Oncol; 2006 May; 24(14):e23-5. PubMed ID: 16682729
[No Abstract] [Full Text] [Related]
3. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
[TBL] [Abstract][Full Text] [Related]
4. Immune reconstitution: the foundation for safe living after an allogeneic hematopoietic stem cell transplantation.
Laffan A; Biedrzycki B
Clin J Oncol Nurs; 2006 Dec; 10(6):787-94. PubMed ID: 17193944
[TBL] [Abstract][Full Text] [Related]
5. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
6. [Mucocutaneous and salivary manifestations of the graft vs host reaction after bone marrow transplantation].
d'Agay MF; Brocheriou C; Kuffer R; Gluckman E; Janin A; Saurat JH
Rev Stomatol Chir Maxillofac; 1984; 85(5):370-4. PubMed ID: 6393313
[TBL] [Abstract][Full Text] [Related]
7. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation.
Prinz E; Keil F; Kalhs P; Mitterbauer M; Rabitsch W; Rosenmayr A; Moser K; Schulenburg A; Lechner K; Greinix HT
Ann Hematol; 2003 May; 82(5):295-8. PubMed ID: 12679886
[TBL] [Abstract][Full Text] [Related]
10. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
11. [Basic and clinical research to improve the outcome of hematopoietic stem cell transplantation].
Teshima T
Rinsho Ketsueki; 2009 Aug; 50(8):617-21. PubMed ID: 19915376
[No Abstract] [Full Text] [Related]
12. Late complications in blood and marrow transplant survivors.
Majhail NS
Minn Med; 2010 Oct; 93(10):45-9. PubMed ID: 21140762
[TBL] [Abstract][Full Text] [Related]
13. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
[TBL] [Abstract][Full Text] [Related]
14. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
16. Graft engineering.
Noga SJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):15-21. PubMed ID: 10877046
[TBL] [Abstract][Full Text] [Related]
17. Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease.
Ringdén O; Lönnqvist B; Hägglund H; Ljungman P; Shanwell A; Lawlor E; Schmitz N
Bone Marrow Transplant; 1995 Dec; 16(6):856-7. PubMed ID: 8750284
[No Abstract] [Full Text] [Related]
18. Protective conditioning for acute graft-versus-host disease.
Lowsky R; Takahashi T; Liu YP; Dejbakhsh-Jones S; Grumet FC; Shizuru JA; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Hoppe RT; Bloch DA; Blume KG; Negrin RS; Strober S
N Engl J Med; 2005 Sep; 353(13):1321-31. PubMed ID: 16192477
[TBL] [Abstract][Full Text] [Related]
19. [Corneal complications after hematopoietic stem cell transplantation].
Mittelviefhaus H; Auw-Hädrich C
Ophthalmologe; 2003 Mar; 100(3):222-9. PubMed ID: 12640552
[TBL] [Abstract][Full Text] [Related]
20. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
